Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCKR | Q14397 | 14/20 | 0.57 |
| ▸ | GCK | P35557 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16778 | 1.00 | GCKR (0.57) | GCKRGCKNPC1LMNASMN1; SMN2 | |
| SCHEMBL16527 | 0.87 | GCKR (0.77) | GCKRGCK | |
| SCHEMBL16129 | 0.87 | GCKR (0.77) | GCKRGCK | |
| SCHEMBL12089328 | 0.86 | GCKR (0.63) | GCKRGCKNPC1LMNASMN1; SMN2 | |
| SCHEMBL12089329 | 0.86 | GCKR (0.63) | GCKRGCKNPC1LMNASMN1; SMN2 | |
| SCHEMBL12089331 | 0.86 | GCKR (0.63) | GCKRGCKNPC1LMNASMN1; SMN2 | |
| SCHEMBL15752 | 0.84 | GCKR (0.77) | GCKRGCK | |
| SCHEMBL18513 | 0.84 | GCKR (0.77) | GCKRGCK | |
| SCHEMBL12078780 | 0.84 | GCKR (0.77) | GCKRGCK | |
| SCHEMBL18385 | 0.84 | GCKR (0.77) | GCKRGCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609081-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | Amgen Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| WO-2012027261-A1 | SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES | AMGEN INC. (US) | 2012-03-01 | — | — | WO | disclosed |